Loading...
•
Mar 31, 2024
Lexicon Pharmaceuticals Q1 2024 Earnings Report
Reported first quarter 2024 financial results and provided a business update.
Key Takeaways
Lexicon Pharmaceuticals reported a net loss of $48.4 million, or $0.20 per share, for the first quarter of 2024. Revenues were $1.1 million, primarily from INPEFA. The company is advancing its pipeline, including a planned NDA resubmission for ZYNQUISTA and initiation of a Phase 3 study for sotagliflozin in HCM. They had $355.6 million in cash and investments as of March 31, 2024.
INPEFA launch in heart failure continues to progress with net sales of $1.1 million, a 63% increase from the previous quarter.
NDA resubmission for ZYNQUISTA as an adjunct to insulin in people with type 1 diabetes and CKD is expected mid-year 2024.
Start-up ongoing for Phase 3 study of sotagliflozin in Hypertrophic Cardiomyopathy, with enrollment expected to begin mid-year 2024.
Enrollment in Phase 2b PROGRESS study of LX9211 in Diabetic Peripheral Neuropathic Pain is on track for expected Q2 2025 topline data.
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals Revenue by Segment
Revenue by Segment
Net Product Revenue
CapyFin.comRoyalties and Other Revenue
CapyFin.com Forward Guidance
Lexicon is focused on the commercial launch of INPEFA, resubmission of the NDA for ZYNQUISTA, and advancing its pipeline programs.
Positive Outlook
- Expansion of market access for INPEFA expected to begin around the middle of this year.
- Planned mid-year resubmission of NDA for ZYNQUISTA.
- Commencement of Phase 3 study of sotagliflozin in hypertrophic cardiomyopathy.
- PROGRESS study of LX9211 in diabetic peripheral neuropathic pain remains on track.
- Selection of LX9851 development candidate for obesity and weight management, now entering IND-enabling studies.
Challenges Ahead
- The company reported a net loss for the quarter.
- Increased research and development expenses compared to the corresponding period in 2023.
- Increased selling, general and administrative expenses compared to the corresponding period in 2023.
- Commercial success of INPEFA is dependent on market access, which is still expanding.
- Clinical development programs are subject to regulatory approvals and potential delays.
Revenue & Expenses
Visualization of income flow from segment revenue to net income